文献速递主动脉疾病

医生改良支架治疗主动脉弓疾病的系统综述

Systematic Review on the Use of Physician-Modified Endografts for the Treatment of Aortic Arch Diseases.
PubMed 文献 · Ann Vasc Surg · 2020-08-05

该系统综述基于截至2020年3月的英文文献,纳入6项研究共239例患者,评估医生改良支架治疗主动脉弓疾病的效果。结果显示技术成功率93.7%,30天死亡率2.9%、卒中/短暂性脑缺血发作2.1%,平均随访33.2个月总死亡率4.6%。作者认为该技术安全高效,尤其适用于需单区2开窗的主动脉夹层,但数据来自高流量经验中心。

要点

  • 医生改良支架治疗主动脉弓疾病技术成功率93.7%,附加手术后达98.3%。
  • 30天死亡率2.9%,卒中/短暂性脑缺血发作2.1%,截瘫和支架诱发新入口均为0.4%。
  • 近70%病例为区2单开窗,67.4%为急诊治疗,主要用于急性/亚急性夹层(64.4%)。

核心结论

  • 医生改良支架治疗主动脉弓疾病安全且高效,尤其适用于需单区2开窗的主动脉夹层。
  • 结果来自高流量经验中心,需审慎评估,无经验中心可考虑由导师指导开展。

研究设计与样本

  • 遵循PRISMA指南的系统综述,检索MEDLINE、EMBASE、Google Scholar和Cochrane Central Register of Controlled Trials。
  • 纳入标准为治疗3例及以上患者且随访至少6个月的研究,排除病例报告。
  • 最终纳入6篇文章,共239例患者进行分析。

主要发现

  • 男性占80.3%,67.4%接受急诊治疗,主要因急性/亚急性夹层(64.4%)。
  • 胸主动脉瘤和/或夹层后弓部动脉瘤为第二治疗原因,占25.9%。
  • 技术成功率为93.7%,附加手术后达98.3%。
  • 30天死亡率2.9%,卒中/短暂性脑缺血发作2.1%,截瘫0.4%,支架诱发新入口0.4%。
  • 平均随访33.2±14.8个月,总死亡率为4.6%。

关键数值与推荐

  • 纳入研究需治疗3例及以上患者且随访至少6个月。
  • 近70%的病例为区2单开窗。

临床怎么用

  • 医生改良支架可用于主动脉弓疾病,尤其适合需区2单开窗的主动脉夹层。
  • 应在高流量经验中心开展,无经验中心可考虑导师指导。

局限性

  • 仅纳入6项研究,样本量有限。
  • 数据来自高流量经验中心,结果可能不适用于低流量中心。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The total endovascular approach is in current evolution, and many series have described variable outcomes for branched technology, chimney techniques, or fenestrated repair; and even a combination of some of them. We aim to describe the current outcomes on physician-modified endograft for the treatment of arch diseases. METHODS: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines were used for this systematic review. The search was applied to MEDLINE, EMBASE, Google Scholar, and Cochrane Central Register of Controlled Trials. We used the following search terms in all possible combinations: home-made, physician-modified, surgeon-modified, on-table modification, hand-made, endograft, endovascular, aortic arch, and TEVAR: a thorough search of the English-language literature published until March 2020 was performed to identify studies using physician-modified endograft for the treatment of arch diseases. Only studies with treatment of 3 patients or more and with a minimum of 6-month follow-up were enrolled in the systematic review, whereas case reports were excluded from the analysis. RESULTS: Six articles participated in the systematic review after the exclusions, including a total of 239 patients for analysis. Four high-volume centers provided data including a high rate of single fenestrations in zone 2, accounting for nearly 70% of the cases. About 80.3% were males, and 67.4% received urgent treatment mainly for acute/subacute dissection (64.4%). Thoracic aortic aneurysm and/or postdissection arch aneurysm was the second leading cause of treatment with 25.9%. There was a technical success of 93.7% reaching up to 98.3% when additional procedures were performed. The 30-day mortality, stroke/transient ischemic attack, paraplegia, and stent-induced new entry rates were 2.9%, 2.1%, 0.4%, and 0.4%, respectively; whereas, overall mortality of the study was 4.6% at a mean follow-up of 33.2 ± 14.8 months. CONCLUSIONS: Endograft modification for aortic arch diseases' treatment demonstrates to be safe and highly effective, especially for aortic dissections needing single zone 2 fenestrations. Although outcomes achieved in the study seem encouraging, these are achieved at high-volume experienced centers, thus, they need to be judiciously evaluated, whereas proctoring may be a good alternative if one patient may benefit from the technique in an unexperienced center.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Reyes Valdivia A, Pitoulias G, Pitoulias A, et al. Systematic Review on the Use of Physician-Modified Endografts for the Treatment of Aortic Arch Diseases. Ann Vasc Surg. 2020. PMID: 32768543. doi:10.1016/j.avsg.2020.07.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。